

BIOSAFETY COMMITTEE MEETING

MINUTES

**The Watertown BioSafety Committee has scheduled a REMOTE ZOOM meeting on
Thursday, January 4, 2024 at 7:00 pm**

PRESENT: Brad Parsons, Chairman, Deborah McEwan, Tim Maguire, Ralph Mele, Mia Lieberman, Maureen Foley, Clerk

In attendance: Linda Scott, Cory Martin, Kathi Breen, Kaylee Schickel, Michele Picard, Mike Thomas, Brandon Linz, Emma West, Durup Sengupta, Sam Perry, John Finn, Amanda Souza, Sarah Blum, Olivia Moody, Ivan Mascanfroni, Raneja Ragmina, Michael Cameron, Lindsey DeVaux, Daniela Cipolletta, Laura Brandano, Paul Nederhoed

CALL TO ORDER: Brad Parsons called the meeting to order 7:02 pm

Minutes

Minutes approvals for December 7, 2023

All in Favor (5,0)

Public Comment

Linda Scott mentioned she was grateful to the committee.

Amendments:

Corner Therapeutics – 300 North Beacon Street

Laura Brandano, VP of Operations gave a short presentation of the company's plans. Derup Sengupta, Chief Scientist explained the use of live virus in the lab space in safety cabinets. Mr. Parsons stated the IBC minutes were excellent and the presentation was detailed. Dr. Lieberman questioned the transportation of the live virus to the vivarium.

Mr. Parsons stated Corner's amendment will not present to the BOH.

Bioinnovation Lab – 134 Coolidge Avenue

Amanda Souza, Lab Operations gave a short presentation referring to the tenants uses of NHP (non-human primate) tissues from commercially sourced vendors. Mr. Parson asked what the volume of organic peroxide will be used. Mr. Mele requested and updated list of flammable chemicals and storage. Dr. McEwan is concerned this amendment should be considered a new application with all the appropriate documentation. Dr. Liebermann would like the minutes from the first IBC minutes from earlier in the year in addition to the minutes that were uploaded to the application.

Mr. Parsons stated Bioinnovation's amendment will not present to the BOH. Bioinnovation must supply an updated biosafety manual and additional IBC minutes before permitting.

Digital Biology Inc. – 313 Pleasant Street

Emma West, Founder gave a short presentation of the company's plans to use frozen NHP tissues sourced from pharmaceutical companies. Dr. Lieberman asked about ASO's and CNS tissues and requested an updated biosafety manual be uploaded to the application. Dr. Maguire asked about the CRISPR editing with additional precautions. CRISPR is not in use presently but there is a plan to in the future.

Mr. Parsons stated Digital's amendment will not present to the BOH. Digital must supply an updated

biosafety manual.

Remix Therapeutics – 100 Forge Road

Michael Cameron, Senior Scientist gave a short presentation of the company's plans to use NHP tissues sourced from a CRO (contract research organization). NHP work will be done in a designated area with BSL2+ precautions and additional training.

Mr. Parsons stated Remix's amendment will not present to the BOH.

Seismic Therapeutics – 85 Walnut Street

Lindsey DeVaux, Lab Manager gave a short presentation of the company's plans to use NHP tissues. NHP and Lenti will have enhanced precautions.

There was much discussion about the new onsite vivarium. The amendment for the vivarium has been tabled until the next meeting.

Mr. Parsons stated Seismic's amendment will not present to the BOH. The permit is approved for Lentivirus and NHP work only.

Kymera Therapeutics – 500 North Beacon Street

Michele Picard, Lab Manager gave a short presentation of the company's plans with the move from 200 Arsenal Yards Blvd to 500 North Beacon Street. Ms. Picard stated the same work will continue in a larger space. Mr. Parsons questioned if Kymera was keeping the vivarium at 200 Arsenal Yards and if larger quantities will be generated. Mr. Parsons questioned how materials will be transported between floors. Mr. Mele questioned the chemistry portion of the lab. Dr. McEwan stated in the list of organisms states Kymera is using generations 2-4 lentivirus but per the IBC minutes indicates 2nd generation. Dr. Lieberman pointed out two BSL2 labs, she asked if materials will be transported. IBC should review the vivarium and have a high-level summary.

Mr. Parsons stated Kymera's amendment will not present to the BOH. The vivarium will not be included in this approved amendment.

Tome Biosciences – 100 Talcott Avenue

Paul Nederhoed, Director of R&D gave a short presentation of the company's expansion within the same building. Changing operations in the space due to the production of viral vectors. Tome is working with fire protection. The new floor plan was uploaded.

Mr. Parsons stated Tome's amendment will not present to the BOH.

Items not Anticipated

Dr. McEwan would want any amendments with NHP's to require screening. Mr. Parsons would like to restructure renewals and have discussion in February meeting. Clarify what is included on agent list in renewals and need to correspond to IBC minutes (an example table). Include fee for amendment. Potentially do renewal and amendment at the same time. Still need to track companies that have not renewed.

Next Meeting

The next meeting will be February 1, 2024

Adjourn

Adjourned at 9:17 PM